Guest guest Posted November 14, 2005 Report Share Posted November 14, 2005 NuFACTOR and its parent company FFF Enterprises are very pleased to announce the launch of a new magazine for patients treated with immune globulin, I.G. Living! I.G. Living! is the only magazine dedicated to bringing healthcare product, community and reimbursement news, along with community perspectives, directly to immune globulin consumers and their healthcare providers. Launching its first bimonthly issue in February-March 2006, I.G. Living! will be distributed for free to patients and their physicians' offices, including practices in immunology, neurology and hematology-oncology. The following are some stories you'll find in our first issue: How Safe Is the U.S. Biopharmaceutical Supply Channel – and Why You Should Care On Your Own: Transitioning Teens I.G. Administration: What's Best for You? PID Parenting I.G. Clinical Trials: Evaluating Participation Legislators of the Year Awards (honoring those who have most helped people with immune deficiencies) Managing the Healthcare Reimbursement Maze As a leading distributor of immune globulin, we are acutely aware of the need for a responsible source of information about the full spectrum of issues affecting patients who rely on immune globulin for their health. We would like to hear your suggestions about the stories that would be most valuable to you. NuFACTOR and FFF are dedicated to providing a responsible source of information about the full spectrum of issues affecting patients who rely on immune globulin for their health, and we hope you will join us in this effort. You can sign up for your free subscription to I.G. Living! at www.igliving.com. We look forward to your becoming a regular reader! Please pass this news along to anyone you think would benefit. Janet, Mom to Brittany, CVID, age 14 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.